The Challenges of ...
Prepared by author on Canva.com

The Challenges of ...

Biological drugs are a relatively new entry into the world of pharmaceuticals, and although pharma giants have always been supporting and establishing biopharma products for a long time and continue to do so due to the legacy of regulatory knowledge, scale-up support and funds from the sales of non-biopharma products (due to the huge lead time for getting biologics into the market), there is a need for a unique identity and distinct support for Biopharma specific requirements.

Case in point, recently Novartis August 2022 had decided to split the Biosimilar portfolio of Sandoz into a separate strategic wing stating that it was in the best interest of the stakeholders.

There are more complexities in the way operations and how business is carried out and it is not only the manufacturing differences between traditional pharma (synthesis) and biopharma (fermentation) that stand out between the two.

Both chemicals and biologicals have differences in nomenclature e.g. API (Active Pharmaceutical Ingredient) for biologics are called DS (Drug Substances), Comparability of the biosimilars is different from the Bioequivalence of the Generics, quality attributes are different, Potency is different from Activity, PK-PD, regulatory & analytical requirements, so on and so forth that it is not easy to have the same rulings/departments/functions, etc. to take the business to the next level (as did Novartis), they need expertise and different training/mindset to really understand and execute the requirements as per the specific understanding as a lot of things can get lost in 'translation'.

Just as preparing a CTD isn't literature writing, business units and marketing units should also have adequate specialized backgrounds and training to realize the full potential of Biopharma.

The stated opinion is based on the opinion and current understanding/experience of the author.

As a business case in general for companies to be successful in both areas (pharma and biopharma), it is imminent or let's say critical that long-term strategies should be set not only in choosing the right products for the future, but also the right infrastructure, capabilities and the right minds working on them to ensure their ongoing success.

Short-term goals need to be anchored or directed to long-term destinations and should not be used to extend the long-term further.

要查看或添加评论,请登录

Nabeel Hamza, M.Sc., MBA的更多文章

  • Inspire, Improvise & Initiate

    Inspire, Improvise & Initiate

    "You get the best efforts from others not by lighting a fire beneath them, but by building a fire within." - Bob Nelson…

  • Networking for the Industrial Lab Mouse

    Networking for the Industrial Lab Mouse

    Busy Looking for Solutions We're all busy at any given time, especially when we are in work mode, sometimes too busy to…

    2 条评论
  • Why do I put my team first?

    Why do I put my team first?

    Receive, Set, Spike. If there is one thing I have learned as an avid volleyball enthusiast, it is that we must always…

  • How the Lions challenged a stereotype

    How the Lions challenged a stereotype

    Whoever had stereotyped the Arab/African people (for business lingo the MEA region) as not being capable to come…

  • Leadership: Teaching Vs. Coaching

    Leadership: Teaching Vs. Coaching

    The reason I chose to do this topic is that Learning and applying leadership skills is something that I am passionate…

  • The Secret Recipe that made 'THE TOP 5 BIOTECH CEOS OF 2022' In less than 3 Minutes

    The Secret Recipe that made 'THE TOP 5 BIOTECH CEOS OF 2022' In less than 3 Minutes

    I picked up a report on the top 25 Biotech CEOs of 2022 the burning question on my mind was, what was the secret…

  • When to ask for help...

    When to ask for help...

    There is nothing wrong with asking for help when you really need it. We may think that exposing our, weaknesses…

  • Boss-um Buddies?

    Boss-um Buddies?

    ‘Can we be friends?’ Managers and team members often contemplate this thought, especially when there isn’t much of a…

    3 条评论
  • Case Study for biosimilar interchangeability FDA (and updates from EMA)

    Case Study for biosimilar interchangeability FDA (and updates from EMA)

    Author's own image as a summary case Definitions (FDA): What is an interchangeable product? An interchangeable product…

  • Why Should I do..? Vs. What Can I do..?

    Why Should I do..? Vs. What Can I do..?

    One of these questions adds Value; While the other questions the value you deliver to the team and Organization. For a…

社区洞察

其他会员也浏览了